Kamada Management

Management criteria checks 3/4

Kamada's CEO is Amir London, appointed in Jul 2015, has a tenure of 8.83 years. total yearly compensation is $861.00K, comprised of 47.5% salary and 52.5% bonuses, including company stock and options. directly owns 0.1% of the company’s shares, worth $331.89K. The average tenure of the management team and the board of directors is 1.9 years and 4.4 years respectively.

Key information

Amir London

Chief executive officer

US$861.0k

Total compensation

CEO salary percentage	47.5%
CEO tenure	8.8yrs
CEO ownership	0.1%
Management average tenure	1.9yrs
Board average tenure	4.4yrs

Recent management updates

Recent updates

Kamada secures $22M extension of Canadian supply tender

Oct 19

Kamada Q2 2022 Earnings Preview

Aug 16

Kamada inks agreement for the distribution of three biosimilar products in Israel

Jan 13

Kamada Looks Cheap AS Takeda Deal Creates Value

Nov 02

CEO Compensation Analysis

How has Amir London's remuneration changed compared to Kamada's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$861k	US$409k	US$8m
Sep 30 2023	n/a	n/a	US$6m
Jun 30 2023	n/a	n/a	US$3m
Mar 31 2023	n/a	n/a	-US$491k
Dec 31 2022	US$684k	US$410k	-US$2m
Sep 30 2022	n/a	n/a	-US$10m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$7m
Dec 31 2021	US$663k	US$412k	-US$2m
Sep 30 2021	n/a	n/a	US$4m
Jun 30 2021	n/a	n/a	US$12m
Mar 31 2021	n/a	n/a	US$15m
Dec 31 2020	US$840k	US$406k	US$17m
Sep 30 2020	n/a	n/a	US$21m
Jun 30 2020	n/a	n/a	US$20m
Mar 31 2020	n/a	n/a	US$23m
Dec 31 2019	US$738k	US$333k	US$22m
Sep 30 2019	n/a	n/a	US$35m
Jun 30 2019	n/a	n/a	US$26m
Mar 31 2019	n/a	n/a	US$26m
Dec 31 2018	US$549k	US$327k	US$22m
Sep 30 2018	n/a	n/a	US$11m
Jun 30 2018	n/a	n/a	US$13m
Mar 31 2018	n/a	n/a	US$12m
Dec 31 2017	US$525k	US$293k	US$7m

Compensation vs Market: Amir's total compensation ($USD861.00K) is below average for companies of similar size in the US market ($USD2.40M).

Compensation vs Earnings: Amir's compensation has been consistent with company performance over the past year.

CEO

Amir London (54 yo)

8.8yrs

Tenure

US$861,000

Compensation

Mr. Amir London has been the Chief Executive Officer at Kamada Ltd. since July 1, 2015. Mr. London served as an Senior Vice President of Business Development at Kamada Ltd.from December 9, 2013 to July 1,...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Amir London	Chief Executive Officer	8.8yrs	US$861.00k	0.10% $ 331.9k
Chaime Orlev	Chief Financial Officer	less than a year	US$509.00k	0.020% $ 64.4k
Eran Nir	Chief Operating Officer	7.5yrs	US$387.00k	0.018% $ 57.5k
Jon Knight	Vice President of US Commercial Operations	no data	US$350.00k	no data
Boris Gorelik	Vice President of Business Development & Strategic Programs	1.9yrs	US$457.00k	no data
David Tsur	Co-Founder & Independent Deputy Chairman of the Board	8.8yrs	US$300.00k	1.06% $ 3.4m
Nir Livneh	VP, General Counsel & Corporate Secretary	less than a year	no data	no data
Hanni Neheman	Vice President of Marketing & Sales	4.3yrs	no data	0.0059% $ 18.9k
Liron Reshef	Vice President of Human Resources	1.3yrs	no data	no data
Shavit Beladev	Vice President of Kamada Plasma	1.9yrs	no data	0.0060% $ 18.9k

1.9yrs

Average Tenure

53yo

Average Age

Experienced Management: KMDA's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
David Tsur	Co-Founder & Independent Deputy Chairman of the Board	8.8yrs	US$300.00k	1.06% $ 3.4m
Leon Recanati	Independent Director	19yrs	no data	3.44% $ 10.9m
Ishay Davidi	Independent Director	4.4yrs	no data	no data
Lilach Asher-Topilsky	Independent Chairman of the Board	4.4yrs	no data	0% $ 0
Assaf Itshayek	Independent External Director	less than a year	no data	no data
Benjamin Dekel	Independent External Director	less than a year	no data	no data
Lilach Payorski	Independent Director	2.4yrs	no data	no data
Karnit Goldwasser	Independent Director	4.4yrs	no data	0% $ 0
Uri Botzer	Independent Director	1.4yrs	no data	no data

4.4yrs

Average Tenure

53yo

Average Age

Experienced Board: KMDA's board of directors are considered experienced (4.4 years average tenure).

Kamada Management

Management criteria checks 3/4

Key information

Recent management updates

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

High number of new directors

Kamada Ltd., Annual General Meeting, Dec 22, 2022

High number of new directors

Recent updates

Kamada Ltd. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kamada Ltd. Provides Revenue Guidance for the Year 2024

Kamada Ltd. to Report Q4, 2023 Results on Mar 06, 2024

Investor sentiment improves as stock rises 23%

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kamada Ltd., Annual General Meeting, Dec 28, 2023

Kamada Ltd. to Report Q3, 2023 Results on Nov 13, 2023

Kamada Ltd. Announces Availability of Product Manufactured by the Company for U.S Commercial Sale and Presentation of New Clinical Data

New minor risk - Shareholder dilution

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kamada Ltd. to Report Q2, 2023 Results on Aug 16, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kamada Ltd. announced that it expects to receive $59.85 million in funding from First Israel Mezzanine Investors Ltd.

Kamada Ltd. to Report Q1, 2023 Results on May 24, 2023

Kamada Ltd. Announces Receipt of Marketing Authorization for Glassia for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Kamada Ltd. Announces U.S. FDA Approval of Its Application to Manufacture CYTOGAM At the Company’s Facility in Israel

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Kamada Ltd. Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® At the Company’s Facility in Israel

Kamada Ltd. Appoints Uri Botzer as Members of Board of Directors

Kamada Announces Planned Transition of Chaime Orlev, Chief Financial Officer, Effective March 15, 2023

Kamada Ltd. Provides Revenue Guidance for the Fiscal Year 2022

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kamada Ltd. to Report Q3, 2022 Results on Nov 22, 2022

High number of new directors

Kamada Ltd., Annual General Meeting, Dec 22, 2022

Kamada Ltd. Updates on Recent Progress Achieved in Ongoing Pivotal Phase 3 InnovAATe Clinical Trial

Kamada secures $22M extension of Canadian supply tender

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Kamada Ltd. Provides Earnings Guidance for the Second Half of Year and Full Year 2022

Kamada Q2 2022 Earnings Preview

Kamada Ltd. to Report Q2, 2022 Results on Aug 17, 2022

Kamada Ltd. Provides Earnings Guidance for the Full Year of 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. Reiterates Earnings Guidance for the Fiscal Year 2022

Kamada Ltd. to Report Q1, 2022 Results on May 17, 2022

High number of new directors

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Kamada Ltd. to Report Q4, 2021 Results on Mar 15, 2022

Kamada Ltd. Acquires Portfolio of Four Plasma-Derived Hyperimmune Commercial Products from Saol Therapeutics

Third quarter 2021 earnings: EPS and revenues miss analyst expectations

Kamada Ltd.(TASE:KMDA) dropped from TA-125 Index

Second quarter 2021 earnings released: EPS US$0.02 (vs US$0.08 in 2Q 2020)

Kedrion Biopharma and Kamada Ltd. Announce FDA Approval of KEDRAB® Label Update, Confirming Safety and Effectiveness in Children

First quarter 2021 earnings released: EPS US$0.06 (vs US$0.12 in 1Q 2020)

Kamada Ltd. (TASE:KMDA) completed the acquisition of Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc.

New 90-day low: US$6.26

Full year 2020 earnings released: EPS US$0.39 (vs US$0.55 in FY 2019)

Revenue and earnings miss expectations

Kamada Ltd. to Report Q4, 2020 Results on Feb 10, 2021

Investor sentiment improved over the past week

New 90-day high: US$7.63

Kamada Ltd. (TASE:KMDA) entered into an agreement to acquire Plasma collection center and certain related rights and assets from Blood and Plasma Research, Inc. for $1.6 million.

Kamada Ltd. Enters into Two New Agreements for the Distribution of Three Biosimilar Products in Israel

Kamada inks agreement for the distribution of three biosimilar products in Israel

New 90-day low: US$6.32

Revenue and earnings beat expectations

Third quarter 2020 earnings released: EPS US$0.15

Kamada Ltd. Appoints Yifat Philip, Esq. as Vice President Legal, General Counsel and Corporate Secretary

Kamada Ltd. to Report Q3, 2020 Results on Nov 11, 2020

Kamada Looks Cheap AS Takeda Deal Creates Value

Market pulls back on stock over the past week

New 90-day low: US$7.86

Kamada Ltd. Signs Agreement with the Israeli Ministry of Health to Supply its Anti-SARS-CoV-2 Plasma-Derived Hyperimmune Immunoglobulin Product for the Treatment of Coronavirus Patients in Israel

New 90-day low: US$8.02

New 90-day high - US$9.95

Kamada Ltd. announced that it has received $25.000002 million in funding